SMARCA2/4 ATPase antagonists are currently in phase I clinical trials for SMARCA2/4-dependent cancers, such as uveal melanoma and acute myeloid leukemia (NCT04879017 and NCT04891757) highlighting the feasibility of this approach. Here, SMARCA2 is linked to uveal melanoma.